Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.

A single intravenous infusion of allogeneic, bone marrow-derived human MSCs was well tolerated in nine patients with moderate-to-severe ARDS, and this phase 1 trial has proceeded to phase 2 testing of M SCs for moderate to severe ARDS with a primary focus on safety and secondary outcomes including respiratory, systemic, and biological endpoints.